Alexey Danilov, ASH 2019: Advancing the Role of BTK Inhibitors in B-Cell Malignancies
At the 61st ASH Annual Meeting & Exposition, Alexey Danilov discusses his presentation: Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management.
1. What have been the most important recent advances in the use of BTK inhibitors in B-cell malignancies? (0:05)
2. What factors should be considered when selecting the most appropriate BTK inhibitors for an individual? (1:27)
3. What are the major obstacles to the first-line use of BTK inhibitors in B-cell malignancies and how can these be overcome? (3:12)
4. What are likely to be the future challenges and research directions in the use of BTK inhibitors for B-cell malignancies? (4:50)
Alexey Danilov is a consult for Janssen, Pharmacyclics, AstraZeneca, Beigene, Verastem, Genentech, Gilead, Nurix, Curis and TG Therapeutics. He has received research funding from AstraZeneca, Gilead, Genentech, Verastem, BMS and Bayer.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Share this Video
Related Videos In Haematological Malignancies
Massimo Breccia, ASH 2022: Asciminib for patients with chronic myeloid leukaemia, the ASC4OPT study
The ASC4OPT study aims to potentially optimize dosing levels of asciminib in patients with chronic myeloid leukaemia in the chronic phase that have previously been treated with 2 lines of tyrosine kinase inhibitors. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the ASCEMBL findings, what we […]
Massimo Breccia, ASH 2022: The limitations of tyrosine kinase inhibitors in chronic myeloid leukaemia and approval status of asciminib
Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the limitations of TKIs in the […]
Shaji Kumar, ASH 2022: Promising new agents enhancing the treatment of multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses some promising new agents for the treatment of multiple myeloma, including immunotherapies like CAR-T cell therapies, as well as data from novel bispecific antibodies in the context of relapsed or refractory multiple myeloma. Abstract 158: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!